By Connor Hart
Pamt commenced a self-tender offer to purchase up to 435,000 shares. The company, which provides truckload and logistics services through its subsidiaries, said the shares account for about 2% of its outstanding common stock. It won't pay less than $14 a share or more than $17 a share, and it expects to pay for the shares largely using available cash and cash equivalents. Shares climb 25%, to $13.91, in after-hours trading.
CXApp posted what it called record annual revenue and said it expects significantly higher demand for its agentic artificial intelligence this year. The workplace-experience-solutions provider said it logged double-digit growth in recurring revenue in 2024 compared with the prior year, driven by higher subscription revenue. Looking forward, it will continue its focus of investing in agentic AI. Shares jump 59%, to $1.28, in post-market trading.
Sangamo Therapeutics entered a licensing agreement with Eli Lilly. Under the deal, the genomic-medicine company Sangamo said Lilly would receive rights to employ STAC-BBB, its proprietary capsid for up to five potential disease targets. Sangamo will receive $18 million as an upfront license fee, and is eligible to receive up to $1.4 billion in additional license fees, milestone payments, and tiered royalties. Shares rise 33%, to 83 cents, in after-hours trading.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
April 03, 2025 19:37 ET (23:37 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。